TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07886268: A Study to Evaluate the Efficacy and Safety of TP-06 for PCED

Sponsor: Tarsus Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,826,000

Rescue Site Savings

+$1,195,200

Unlock Full NCT07886268 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07886268 Rescue Dossier →